StemCell Therapy

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

International Stem Cell Corporation (OTCBB: ISCO) announced today that Kenneth Aldrich, Chairman, will be presenting at the 2011 Southern California Investor Conference on Monday, August 29, 2011 at 1:30 p.m. Pacific (4:30 p.m. Eastern). The conference takes place at The Island Hotel in Newport Beach, California.


The Southern California Investor Conference is the only conference focused exclusively on the wealth of exciting growth companies from Southern California. The annual one-day conference features more than 35 companies from the region presenting to attendees from throughout the nation. The conference is open to the public and investors can find a list of 2011 presenting companies and registration information at http://www.CaliforniaStocks.com


A webcast of the International Stem Cell Corporation presentation will be accessible online at http://events.powerstream.net/002/00271/20110829_SCIC_T2/ or from the link on the Company's web site at http://www.internationalstemcell.com. An archived version will be available for 30 days.


About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells with minimal immune rejection after transplantation into hundreds of millions of individuals of differing genders, ages and racial background. This offers the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, and cell-based skin care products through its subsidiary Lifeline Skin Care. More information is available at http://www.internationalstemcell.com.


To subscribe to receive ongoing corporate communications, please click on the following link:http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.


International Stem Cell Corporation
Kenneth C Aldrich, Chairman
760-940-6383
kaldrich@intlstemcell.com
or
Lippert/Heilshorn & Associates
Don Markley
310-691-7100
dmarkley@lhai.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Franklin is a patient with spinal cord injury. This video is the experience of Franklin R. who underwent stem cell treatment to improve his condition after an accident that left him paraplegic.

Read the original here:
Spinal Cord Injury - Stem Cell Therapy

Medicenter, a Stem Cells clinic in Guatemala, Central America. Mr. Gemperline had a stem cell transplantation

More here:
Stem cell therapy in Guatemala - (closer than China)

Cathy received stem cell and adipose derived stem cell injections to help her with severe hip problem. She has been in severe pain for 8 months until Dr.

See the original post here:
Stem Cell Therapy - Treatment for Severe Hip Pain

Continued here:
Stroke Victim Improved With Stem Cell Therapy. More at http://www.stemcellfusion.com

Recent research from Scotland reinforces the longstanding medical opinion that vitamin D deficiency leads to a significantly increased risk of bone fractures.

Among people with hip fractures referred to the Scottish fracture liaison service, 98 percent test positive for serious deficiencies in vitamin D. Supplementation with the vitamin, on the other hand, significantly reduces the risk of repeat fractures.

"Taking a supplement can make a difference quite quickly," said Stephen Gallacher, head of the liaison service. "Bone density can increase by 20 percent in a few months with enough vitamin D."

"We have found we can reduce fractures by something like 30 to 50 percent. It is our belief that we can significantly reduce the risk of fractures in the population by giving people anti-osteoporosis therapy and vitamin D supplements."Read more...

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

International Stem Cell Corporation and Subsidiaries (A Development Stage Company) Condensed Consolidated Statements of Financial Condition June 30, 2011 December 31, 2010 (Restated)(1) (Unaudited) Assets Cash and cash equivalents $ 3,581,933 $ 5,782,027 Accounts receivable 341,666 738,506 Inventory 1,329,433 856,083 Prepaid expenses and other current assets 290,196 228,338 Total current assets 5,543,228 7,604,954 Property and equipment, net 1,495,916 1,295,328 Patent licenses, net 1,056,562 986,714 Deposits and other assets 16,279 39,812 Total assets $ 8,111,985 $ 9,926,808 Liabilities and Stockholders' Equity Accounts payable $ 1,032,531 $ 582,824 Accrued expenses 855,315 545,781 Deferred revenue 137,834 759,667 Advances 250,000 250,000 Warrants to purchase common stock 1,027,171 2,399,605 Total current liabilities 3,302,851 4,537,877 Commitments and contingencies Stockholders' Equity Common stock, $.001 par value, 200,000,000 shares authorized, 76,599,928 shares and 74,771,107 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 76,600 74,771 Convertible preferred stock, $.001 par value, 20,000,000 shares authorized, 2,800,043 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 2,800 2,800 Subscription receivable on common stock - (4,875 ) Additional paid-in capital 59,780,363 56,170,006 Deficit accumulated during the development stage (55,050,629 ) (50,853,771 ) Total stockholders' equity 4,809,134 5,388,931 Total liabilities and stockholders' equity $ 8,111,985 $ 9,926,808 (1) The Company restated its financial statements for the year ended December 31, 2010, and the quarter ended March 31, 2011. International Stem Cell Corporation and Subsidiaries (A Development Stage Company) Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, Inception (August 2001) through June 30, 2011 (Restated)(1) 2011 2010 (Restated)(1) 2011 (Restated)(1) 2010 (Restated)(1) Revenues Product sales $ 1,114,309 $ 441,118 $ 2,629,225 $ 713,744 $ 5,728,390 Royalties and license - - - - 135,000 Total revenue $ 1,114,309 $ 441,118 $ 2,629,225 $ 713,744 $ 5,863,390 Development expenses Cost of sales 362,131 214,330 791,125 360,706 2,506,597 Research and development 1,128,869 754,000 2,132,279 1,338,069 15,992,557 Marketing 345,800 291,576 664,006 424,994 3,063,155 General and administrative 2,135,732 2,033,615 4,368,470 3,408,821 27,692,292 Total development expenses 3,972,532 3,293,521 7,955,880 5,532,590 49,254,601 Loss from development activities (2,858,223 ) (2,852,403 ) (5,326,655 ) (4,818,846 ) (43,391,211 ) Other income (expense) Settlement with related company - - - - (92,613 ) Miscellaneous expense (12,040 ) (256 ) (11,140 ) (20,649 ) (28,652 ) Dividend income - 350 - 25,999 92,875 Interest expense - (6,805 ) - (14,079 ) (2,225,074 ) Sublease income 2,450 2,125 4,650 3,525 303,083 Change in market value of warrants 478,669 7,083,365 1,349,518 (1,347,960 ) (2,380,664 ) Total other income (expense) 469,079 7,078,779 1,343,028 (1,353,164 ) (4,331,045 ) Income (loss) before income taxes (2,389,144 ) 4,226,376 (3,983,627 ) (6,172,010 ) (47,722,256 ) Provision for income taxes - - - - 6,800 Net income (loss) $ (2,389,144 ) $ 4,226,376 $ (3,983,627 ) $ (6,172,010 ) $ (47,729,056 ) Dividends on preferred stock $ (107,203 ) $ - $ (213,231 ) $ (1,238,067 ) $ (7,751,380 ) Net income (loss) attributable to common stockholders $ (2,496,347 ) $ 4,226,376 $ (4,196,858 ) $ (7,410,077 ) $ (55,480,436 ) Basic earnings per common share $ (0.03 ) $ 0.06 $ (0.06 ) $ (0.11 ) Diluted earnings per common share $ (0.03 ) $ 0.04 $ (0.06 ) $ (0.11 ) Share used in per share calculations: Weighted average shares outstanding 76,340,016 68,676,504 75,842,071 64,789,250 Weighted average shares outstanding on a Fully Diluted Basis 76,340,016 114,797,830 75,842,071 64,789,250 (1) The Company restated its financial statements for the year ended December 31, 2010, and the quarter ended March 31, 2011. International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com Or Ray Wood, CFO 760-940-6383 rwood@intlstemcell.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Recent research from Scotland reinforces the longstanding medical opinion that vitamin D deficiency leads to a significantly increased risk of bone fractures.

Among people with hip fractures referred to the Scottish fracture liaison service, 98 percent test positive for serious deficiencies in vitamin D. Supplementation with the vitamin, on the other hand, significantly reduces the risk of repeat fractures.

"Taking a supplement can make a difference quite quickly," said Stephen Gallacher, head of the liaison service. "Bone density can increase by 20 percent in a few months with enough vitamin D."

"We have found we can reduce fractures by something like 30 to 50 percent. It is our belief that we can significantly reduce the risk of fractures in the population by giving people anti-osteoporosis therapy and vitamin D supplements."Read more...

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

International Stem Cell Corporation and Subsidiaries (A Development Stage Company) Condensed Consolidated Statements of Financial Condition June 30, 2011 December 31, 2010 (Restated)(1) (Unaudited) Assets Cash and cash equivalents $ 3,581,933 $ 5,782,027 Accounts receivable 341,666 738,506 Inventory 1,329,433 856,083 Prepaid expenses and other current assets 290,196 228,338 Total current assets 5,543,228 7,604,954 Property and equipment, net 1,495,916 1,295,328 Patent licenses, net 1,056,562 986,714 Deposits and other assets 16,279 39,812 Total assets $ 8,111,985 $ 9,926,808 Liabilities and Stockholders' Equity Accounts payable $ 1,032,531 $ 582,824 Accrued expenses 855,315 545,781 Deferred revenue 137,834 759,667 Advances 250,000 250,000 Warrants to purchase common stock 1,027,171 2,399,605 Total current liabilities 3,302,851 4,537,877 Commitments and contingencies Stockholders' Equity Common stock, $.001 par value, 200,000,000 shares authorized, 76,599,928 shares and 74,771,107 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 76,600 74,771 Convertible preferred stock, $.001 par value, 20,000,000 shares authorized, 2,800,043 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 2,800 2,800 Subscription receivable on common stock - (4,875 ) Additional paid-in capital 59,780,363 56,170,006 Deficit accumulated during the development stage (55,050,629 ) (50,853,771 ) Total stockholders' equity 4,809,134 5,388,931 Total liabilities and stockholders' equity $ 8,111,985 $ 9,926,808 (1) The Company restated its financial statements for the year ended December 31, 2010, and the quarter ended March 31, 2011. International Stem Cell Corporation and Subsidiaries (A Development Stage Company) Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended June 30, Six Months Ended June 30, Inception (August 2001) through June 30, 2011 (Restated)(1) 2011 2010 (Restated)(1) 2011 (Restated)(1) 2010 (Restated)(1) Revenues Product sales $ 1,114,309 $ 441,118 $ 2,629,225 $ 713,744 $ 5,728,390 Royalties and license - - - - 135,000 Total revenue $ 1,114,309 $ 441,118 $ 2,629,225 $ 713,744 $ 5,863,390 Development expenses Cost of sales 362,131 214,330 791,125 360,706 2,506,597 Research and development 1,128,869 754,000 2,132,279 1,338,069 15,992,557 Marketing 345,800 291,576 664,006 424,994 3,063,155 General and administrative 2,135,732 2,033,615 4,368,470 3,408,821 27,692,292 Total development expenses 3,972,532 3,293,521 7,955,880 5,532,590 49,254,601 Loss from development activities (2,858,223 ) (2,852,403 ) (5,326,655 ) (4,818,846 ) (43,391,211 ) Other income (expense) Settlement with related company - - - - (92,613 ) Miscellaneous expense (12,040 ) (256 ) (11,140 ) (20,649 ) (28,652 ) Dividend income - 350 - 25,999 92,875 Interest expense - (6,805 ) - (14,079 ) (2,225,074 ) Sublease income 2,450 2,125 4,650 3,525 303,083 Change in market value of warrants 478,669 7,083,365 1,349,518 (1,347,960 ) (2,380,664 ) Total other income (expense) 469,079 7,078,779 1,343,028 (1,353,164 ) (4,331,045 ) Income (loss) before income taxes (2,389,144 ) 4,226,376 (3,983,627 ) (6,172,010 ) (47,722,256 ) Provision for income taxes - - - - 6,800 Net income (loss) $ (2,389,144 ) $ 4,226,376 $ (3,983,627 ) $ (6,172,010 ) $ (47,729,056 ) Dividends on preferred stock $ (107,203 ) $ - $ (213,231 ) $ (1,238,067 ) $ (7,751,380 ) Net income (loss) attributable to common stockholders $ (2,496,347 ) $ 4,226,376 $ (4,196,858 ) $ (7,410,077 ) $ (55,480,436 ) Basic earnings per common share $ (0.03 ) $ 0.06 $ (0.06 ) $ (0.11 ) Diluted earnings per common share $ (0.03 ) $ 0.04 $ (0.06 ) $ (0.11 ) Share used in per share calculations: Weighted average shares outstanding 76,340,016 68,676,504 75,842,071 64,789,250 Weighted average shares outstanding on a Fully Diluted Basis 76,340,016 114,797,830 75,842,071 64,789,250 (1) The Company restated its financial statements for the year ended December 31, 2010, and the quarter ended March 31, 2011. International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com Or Ray Wood, CFO 760-940-6383 rwood@intlstemcell.com

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Ying Liu, a Scripps Clinic researcher in the lab of stem cell scientist Jeanne Loring, discusses the biological underpinnings of the technology for using induced pluripotent stem cells for treated ALS, or Lou Gehrig's disease. For more information about the Loring lab, go to http://www.scripps.edu

Go here to see the original:
Ying Liu discusses IPS cell therapy for ALS

Medicenter, a Stem Cells clinic in Guatemala, Central America.

Excerpt from:
Stem cell therapy in Guatemala - (closer than China)

Dr. Damon Noto at Spine and Joint Center in New Jersey offers cutting-edge, non-invasive regenerative medicine including stem cell treatment and PRP to treat patients with spinal and joint problems.

Read more from the original source:
Stem Cell Therapy (Regenerative Medicine) in New Jersey

I'm not going to fool anyone into believing I'm a therapeutic product development expert but that's not going to stop me from making a few humble observations in light of the Dendreon "fiasco" of last week which I have no doubt will one day be considered an unfortunate pothole on their road to eventual success.

(though perhaps not before certain current management finds themselves polishing their CVs or retiring to spend their time alternating between their yachts and the courtroom defending their questionable stock trading antics)

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

International Stem Cell Corp (OTCBB:ISCO) is a company to watch this year, with several promising developments in store, according to a conference call with investors this morning.


The company, whose parthenogenetic stem cell technology can be used to derive pluripotent stem cells, meaning they can be transformed into any cell type in the body, has many important advantages at its fingertips.


Regenerative medicine is a market that is set to boom in the coming years, as more and more companies are developing therapies based on stem cell use. International Stem Cell's long-term goal is to be a universal supplier of stem cells for not just one, but a host of therapies.


The company's parthenogenetic stem cells are derived from unfertilized eggs, avoiding the ethical issues behind the destruction of viable human embryos, and giving cell-therapy companies one big reason to chose International Stem Cell as their supplier of choice when the time is right.
These parthenogenetic cells, like embryonic cells, also have the capacity to become almost any cell type in the body, but have demonstrated they are better in terms of the immune system, as one single stem cell line can be genetically matched to millions of people, reducing the need for immunosuppressants.


The company holds the world's largest collection of research-grade human parthenogenetic stem cell (hpSC) lines, which it uses along with its partners to investigate cellular therapies for a number of incurable human diseases.


Its plan is to establish a US bank of its clinical-grade human parthenogenetic stem cells that will be capable of being immune-matched to millions of patients, so that a physician could call up and request a specific cell type for people. The company, which recently received approvals to enroll around 3 US donors for its bank, already has a collection of ten human parthenogenetic stem cell lines used for research purposes, which were derived outside the US.


These cell lines could potentially be used to cure a number of diseases, including cancer, heart disease, liver disease, among many others. Already, the company has several trials in the works, and has successfully demonstrated in pre-clinical animal studies that its stem cells can be used to create viable liver cells.


Currently, efficacy tests in rat models are in progress for the liver cells, with results anticipated soon. If successful, the company said it plans on aggressively initiating the FDA process, with the aim of beginning first stage clinical trials sometime in 2012. The hope is that International Stem Cell will attain Fast Track designation, as few alternative options are available to patients suffering from liver disease.


The company also has trials in the works for Parkinson's disease and diseases of the eye, and is actively looking for collaborative or joint venture opportunities, as well as in-licensing and out-licensing arrangements.


In addition to its hugely potentially valuable stem cell therapy business, the company also two other operations that are set to generate revenue in the meantime. Lifeline Cell Technology, which saw sales grow by 35% in the first quarter, develops manufactures and markets the Lifeline brand of cell-culture products, which are used by researchers to grow human cells for pre-clinical research.


The subsidiary's products are developed using parent International Stem Cell's technology, and the company expects that as trials for researchers progress into more advanced stages, its technology will be embedded in this progress, potentially generating hundreds of millions of revenue.


In the last quarter, Lifeline Cell gained over 200 new customers due to new product introductions and the development of distribution channels internationally, a strategy it plans to continue.


Lastly, International Stem Cell's Lifeline Skin Care business sells skin care products based on its stem cells, having a very successful launch at the end of last year. The company planned on selling 1,000 products, but sold 7,000 initially, and plans to aggressively kick start major marketing initiatives again in September.


International Stem Cell is a company with scores of upside potential, and though future capital raising has not been ruled out, it has a facility that allows it to draw equity as necessary.
Register here to be notified of future International Stem Cell articles